Trials / Completed
CompletedNCT06434961
The Trial of SHR6508 in Secondary Hyperparathyroidism
A Multicenter, Randomised, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 498 (actual)
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy and safety of SHR6508 among Chinese patients with secondary hyperparathyroidism of chronic kidney disease treated by maintenance hemodialysis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR6508 plus oral placebo tablets | SHR6508 plus oral placebo tablets |
| DRUG | Cinacalcet plus intravenous placebo | Cinacalcet plus intravenous placebo |
Timeline
- Start date
- 2024-06-14
- Primary completion
- 2025-09-29
- Completion
- 2025-11-11
- First posted
- 2024-05-30
- Last updated
- 2025-12-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06434961. Inclusion in this directory is not an endorsement.